Delaware
|
|
001-40739
|
|
86-3218736
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Title of Each Class:
|
|
Trading Symbol
|
|
Name of Each Exchange on which Registered
|
Common
Stock, par value $0.0001 per share
|
|
DRMA
|
|
The
Nasdaq Capital Market
|
Warrants,
exercisable for one share of Common Stock
|
|
DRMAW
|
|
The
Nasdaq Capital Market
|
Exhibit No.
|
|
Description
|
|
Press
Release, dated September 27, 2021, issued by Dermata Therapeutics,
Inc. entitled “Dermata Therapeutics, Inc. Reports Second
Quarter 2021 Financial Results and Provides a Corporate
Update.”
|
|
|
DERMATA
THERAPEUTICS, INC.
|
|
|
|
|
Dated:
September 27, 2021
|
By:
|
/s/ Gerald T. Proehl
|
|
|
Gerald
T. Proehl
|
|
|
Chief
Executive Officer
|
|
June 30, 2021
|
December 31, 2020
|
|
(unaudited)
|
|
Assets
|
|
|
Cash
|
$427,202
|
$530,400
|
Other
current assets
|
709,662
|
75,053
|
Total
assets
|
1,136,864
|
605,453
|
Liabilities
|
|
|
Accounts
payable
|
881,306
|
104,276
|
Accrued
liabilities
|
586,516
|
133,477
|
Convertible
notes
|
174,844
|
2,989,479
|
Debt
|
-
|
556,160
|
Total
liabilities
|
1,642,666
|
3,783,392
|
Deficit
|
(505,802)
|
(3,177,939)
|
Total liabilities and deficit
|
$1,136,864
|
$605,453
|
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
||
|
2021
|
2020
|
2021
|
2020
|
Operating expenses
|
|
|
|
|
Research
and development (1)
|
$867,197
|
$411,949
|
$1,547,785
|
$1,373,053
|
General
and administrative (1)
|
462,772
|
380,837
|
2,043,957
|
768,310
|
Total
operating expenses
|
1,329,969
|
792,786
|
3,591,742
|
2,141,363
|
Loss
from operations
|
(1,329,969)
|
(792,786)
|
(3,591,742)
|
(2,141,363)
|
Interest
expense, net
|
1,823
|
28,863
|
44,958
|
101,459
|
Net loss
|
$(1,331,792)
|
$(821,649)
|
$(3,636,700)
|
$(2,242,822)
|
Net
loss per common share, basic and diluted
|
$(0.70)
|
$(0.43)
|
$(1.90)
|
$(1.17)
|
Weighted
average common shares
|
|
|
|
|
outstanding,
basic and diluted
|
1,911,009
|
1,911,009
|
1,911,009
|
1,911,009
|
|
|
|
|
|
(1) Includes the following stock-based compensation
expense
|
|
|
|
|
Research
and development
|
$29,744
|
$-
|
$279,971
|
$-
|
General
and administrative
|
$84,243
|
$-
|
$994,065
|
$-
|
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